Translation of novel and repurposed drugs to address the acute and late effects of mustard exposure
Translation of novel and repurposed drugs to address the acute and late effects of mustard exposure
批准号:
10242669
负责人:
Kurt Lu
金额:
$77.34万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-08-01 至 2024-07-31
关键词:
AcuteAddressAdrenal GlandsAftercareApoptosisAttenuatedBindingBioavailableBiological MarkersBloodBlood VesselsBone MarrowBone Marrow CellsBone Marrow SuppressionBullaCell DeathCessation of lifeChemical WeaponsChemicalsCholecalciferolClinicalClinical MedicineClinical ResearchCollaborationsCongestive Heart FailureCutaneousDataDecontaminationDepositionDevicesDiureticsDoseEdemaEffectivenessEffector CellEpidemiologyErythemaEssential HypertensionEventExposure toExtravasationEyeFluid overloadFunctional disorderFutureGlycolatesGoalsGrantHalf-LifeHealthHematopoiesisHemorrhageHumanITGAM geneImmuneIndurationInfiltrationInflammationInflammation MediatorsInflammatoryInjuryInnate Immune ResponseInnate Immune SystemInterleukin-1 betaInterleukin-6InterventionKidneyLate EffectsLesionLigandsLiverLungMacrophage ActivationMarrowMechlorethamineMediatingMineralocorticoid ReceptorModelingModernizationMonitorMorbidity - disease rateMusMustardMustard GasMyeloid CellsMyelosuppressionNecrosisOralOrganOsteoclastsPainPathologyPatient Outcomes AssessmentsPatientsPeptide HydrolasesPharmaceutical PreparationsPhysiologicalPlasmaPolymersPotassiumProductionProtocols documentationPublic HealthRadiationReactionReactive Nitrogen SpeciesReactive Oxygen SpeciesRednessRegimenResearchResearch PersonnelSafetySamplingSignaling MoleculeSiteSkeletal boneSkinSkin TissueSkin injurySodium ChlorideSpironolactoneSpleenSunburnSurfaceSwellingTNF geneTechniquesTestingThickTimeTissuesToxic effectToxicant exposureTranslatingTranslationsUnited StatesUniversitiesUniversity HospitalsUp-RegulationVesicantsVitamin AVitamin DWaterWorkWorld War IWound modelsbisphosphonatecarboxylateclinical trial implementationcytokine release syndromecytopeniacytotoxicdesigndrug repurposingexperienceexperimental studyhuman subjectin vivointerestmacrophagemonocytemortalitymouse modelmultidisciplinarynovelnovel therapeuticspamidronatepillpreventprotective effectrecruitresponseskin lesionskin woundstatisticssystemic toxicitytissue injurytranslational approachtranslational studyweaponswound healing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Countermeasure protocols of mustard decontamination and neutralization may protect exposed
surfaces of the skin, eyes, and lungs when administered immediately after exposure. However, this may not
be adequate to address the delayed onset of myelosuppression and disrupted hematopoiesis associated with
mustard exposure. The impact of the current proposal is to provide a comprehensive countermeasure regimen
that addresses both the acute and delayed detrimental effects of mustard exposure mediated by acute skin
inflammation and the innate immune system, specifically macrophage hyper-activation.
NM-mediated tissue injury of the skin results in rapid epidermal disruption and vascular leakage
resulting edema and painful inflammation. Following the initial injury is an influx of activated inflammatory
monocytes and macrophages. Release of macrophage-mediated soluble signaling molecules promotes a pro-
inflammatory state which amplifies other cytotoxic activities including release of reactive nitrogen species
iNOS, reactive oxygen species, and induction of proteolytic enzymes. Furthermore, these activated iNOS-
producing macrophages are critically involved in mediating and exacerbating systemic toxicities.
We propose to use a multidisciplinary translational approach to modulate skin inflammation and
macrophage activity using in vivo techniques in mouse and human studies. We will study the effect of
spironolactone and bisphosphonates (BPs) in combination with vitamin D to inhibit the production of pro-
inflammatory factors including; TNFα, and iNOS in the skin and in activated macrophages. These drugs have
been in clinical use for many years with known safety and toxicity profiles. Spironolactone is a potassium-
sparing diuretic (water pill) that has been safely used for five decades to treat essential hypertension, fluid
overload and edema in patients with congestive heart failure and other kidney pathologies. While much
information has been accumulated on the physiopathology of spironolactone on the mineralocorticoid receptor
(MR) and the adrenal glands, the effect of MR ligands on non-classical targets such as the skin has found new
and exciting potential applications. We hereby propose that spironolactone being a weak diuretic has sufficient
capacity to reduce water content of edematous skin lesions as a way to accelerate wound healing. The use of
spironolactone may have benefits in limiting edema and painful skin inflammation. BPs are medications that
has been used for over 40 years. In addition to the skeletal bones, these drugs deposit in the skin, liver,
spleen, and bone marrow which aligns with our research interest as they represent organs and tissues that
may be reservoirs and/or targets for activated macrophages. Furthermore, BPs deposit and have long-lasting
effects in the tissue. We propose to use BPs in conjunction with high dose vitamin D3 as countermeasures to
NM exposure. Lastly, as a systemic treatment for the most toxic exposure, we propose to use a novel immune
modifying microparticle (IMPs) which are derived from clinical polymers. Upon binding and engulfment of IMPs,
macrophages are sequestered for degradation in the liver and spleen. The strategy with IMPs represents a
new aspect of this grant to target severe systemic toxicity. To validate and determine the translational
significance of BPs and vitamin D3 in suppressing skin inflammation following mustard exposure, we designed
a human clinical study using UV (solar spectrum radiation) as a surrogate for mustard exposure in healthy
human subjects to expedite future translational studies. It is well known that sunburn exposure leads to
redness, swelling, vesication, and activation of macrophages in the skin including upregulation of iNOS and
TNFα. Information from this human clinical study will be informative and confirmatory of the use of our
proposed countermeasures.
Our assembled team involve co-investigators from different centers within and outside the university
and hospital. The team of co-investigators and consultants will have oversight of the project, helping to identify
new opportunities and complementary approaches drawing from expertise in: dermatopharmacology;
inflammation and macrophages; vitamin D; skin and tissue pathology; clinical trials implementation and
regulatory compliance; statistics and epidemiology - all critical to the translation of this study into a practical
intervention.
This is a novel and highly translational approach to develop potential countermeasure to address key
morbidity and mortality factors from mustard exposure. Spironolactone, bisphosphonates, and vitamin D are a
widely available and inexpensive and, if shown to be beneficial, could have a broad public health impact in the
event of chemical weapon exposure.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Topical and systemic interventions for mustard-induced skin injury
-
批准号:10682629
-
项目类别:
-
资助金额:$56.59万
-
财政年份:2021
-
负责人:Kurt Lu
-
依托单位:
Core A; Administrative Core
-
批准号:10282407
-
项目类别:
-
资助金额:$39.81万
-
财政年份:2021
-
负责人:Kurt Lu
-
依托单位:
Topical and systemic interventions for mustard-induced skin injury
-
批准号:10490418
-
项目类别:
-
资助金额:$66.1万
-
财政年份:2021
-
负责人:Kurt Lu
-
依托单位:
Topical and systemic interventions for mustard-induced skin injury
-
批准号:10282411
-
项目类别:
-
资助金额:$39.81万
-
财政年份:2021
-
负责人:Kurt Lu
-
依托单位:
Translation & trials: advancing medical countermeasure development
-
批准号:10282413
-
项目类别:
-
资助金额:$39.81万
-
财政年份:2021
-
负责人:Kurt Lu
-
依托单位:
Translation & trials: advancing medical countermeasure development
-
批准号:10682633
-
项目类别:
-
资助金额:$63.44万
-
财政年份:2021
-
负责人:Kurt Lu
-
依托单位:
Core A; Administrative Core
-
批准号:10682617
-
项目类别:
-
资助金额:$26.9万
-
财政年份:2021
-
负责人:Kurt Lu
-
依托单位:
Translation & trials: advancing medical countermeasure development
-
批准号:10490423
-
项目类别:
-
资助金额:$65.84万
-
财政年份:2021
-
负责人:Kurt Lu
-
依托单位:
Core A; Administrative Core
-
批准号:10490408
-
项目类别:
-
资助金额:$26.73万
-
财政年份:2021
-
负责人:Kurt Lu
-
依托单位:
Translation of novel and repurposed drugs to address the acute and late effects of mustard exposure
-
批准号:10007605
-
项目类别:
-
资助金额:$77.54万
-
财政年份:2018
-
负责人:Kurt Lu
-
依托单位:
Translation of novel and repurposed drugs to address the acute and late effects of mustard exposure
-
批准号:9145458
-
项目类别:
-
资助金额:$80.0万
-
财政年份:2017
-
负责人:Kurt Lu
-
依托单位:
Amelioration of Vesicant-Induced Skin Injury by High Dose 25-Hydroxyvitamin D
-
批准号:8722316
-
项目类别:
-
资助金额:$77.03万
-
财政年份:2012
-
负责人:Kurt Lu
-
依托单位:
Amelioration of Vesicant-Induced Skin Injury by High Dose 25-Hydroxyvitamin D
-
批准号:8333049
-
项目类别:
-
资助金额:$77.03万
-
财政年份:2012
-
负责人:Kurt Lu
-
依托单位:
Amelioration of Vesicant-Induced Skin Injury by High Dose 25-Hydroxyvitamin D
-
批准号:8545673
-
项目类别:
-
资助金额:$78.9万
-
财政年份:2012
-
负责人:Kurt Lu
-
依托单位:
Amelioration of Vesicant-Induced Skin Injury by High Dose 25-Hydroxyvitamin D
-
批准号:8931701
-
项目类别:
-
资助金额:$95.5万
-
财政年份:2012
-
负责人:Kurt Lu
-
依托单位:
海外基金